Sagicor Financial Company Ltd.

Sagicor Financial Company Ltd. Earnings Recaps

SFC.TO Financials 2 recaps
Next earnings: November 11, 2026 (estimated) · full calendar
Q2 2026 Aug 15, 2026

Sagicor’s shares dropped 3.6% following disappointing core earnings in the legacy life block and margin pressure despite steady new business; cautious investor sentiment appears driven by deceleration in key insurance experience and the impact of reinsurance contract modifications on premium growth.

Key takeaways
  • Core earnings to shareholders rose to $34 million in Q2, up from $25 million in Q1, helped by improved insurance experience and investment portfolio performance.
  • Legacy life block insurance experience losses weighed on Sagicor Life USA’s core earnings, dropping to $6 million and dragging overall segment profitability.
  • Net CSM declined 7% quarter-over-quarter at Sagicor Life due to reinsurance contract changes offsetting organic growth.
  • Sagicor Canada and Jamaica produced solid new business and investment returns but currency headwinds reduced reported net CSM.
  • The company remains well capitalized with LICAT ratio at 134% and maintained dividend payments, but cautious market reaction suggests skepticism about sustainability of margin gains and legacy block performance.
Q3 2025 Nov 15, 2025

Sagicor Financial delivered a robust third quarter in 2025, achieving a 45% increase in core earnings to $35 million, driven by strong performance across Canadian and Caribbean operations, despite revenue declines attributed to actuarial adjustments.

Key takeaways
  • Core earnings to shareholders rose 45% YoY to $35 million, reflecting broad-based profitability across segments.
  • Total revenues decreased to $974 million from $1.1 billion a year ago, influenced by actuarial assumption changes.
  • Sagicor Canada's net income increased to $53 million, benefiting from favorable mortality experience and market-related impacts.
  • Sagicor Life USA reported a 16% growth in new business production to $335 million, although core earnings fell due to adverse mortality claims.
  • Strong results from Sagicor Jamaica included a $12 million contribution to core earnings, buoyed by sales growth and improved net interest margins.